About this item:

115 Views | 256 Downloads

Author Notes:

Henry Wu, MD, Department of Medicine, Emory University School of Medicine, 550 Peachtree St NE, MOT 7, Atlanta, GA 30308, USA. Email: hmwu@emory.edu

B. A. and H. M. W. conceived the study and analytic approach. B. A. and X. Y. collected the data and performed the analysis. Z. S., S. E., and C. M. provided research and clinical guidance for the study design and interpretation. B. A. and H. M. W. drafted the manuscript, and all authors contributed significant feedback for the final manuscript.

The authors would like to thank Penny Castellano, Deena Gilland, Benjamin Albrecht, MaryBeth Sexton, Denise Moultrie, Sabrina Nail, Laurie Wright, Jodi Roberts, Michelle Mott, Michelle Cellai, Jessica Fairley, Tenacia Norris, and Connor Flynn.

All authors: No reported conflicts of interest.

Subjects:

Research Funding:

Data analysis performed by B. A. is supported by the Health Resources and Services Administration of the US Department of Health and Human Services (award number T1MHP39056).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Immunology
  • Infectious Diseases
  • Microbiology
  • COVID-19
  • monoclonal antibodies
  • SARS-CoV-2
  • therapeutics

Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019

Tools:

Journal Title:

OPEN FORUM INFECTIOUS DISEASES

Volume:

Volume 8, Number 7

Publisher:

, Pages ofab315-ofab315

Type of Work:

Article | Final Publisher PDF

Abstract:

We compared rates of emergency department visits or hospitalizations among ambulatory coronavirus disease 2019 (COVID-19) patients treated with monoclonal antibody (mAb) therapy (n=305) vs untreated patients (n=6354). Treatment was associated with decreased encounters within 30 days (adjusted odds ratio, 0.23 [95% confidence interval,. 15-.36]). Our findings support treatment of acute COVID-19 with mAbs.

Copyright information:

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/rdf).
Export to EndNote